Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)
At a glance
Conditions
NCT05787639
Where you'd take part
This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Oregon Health and Science University
Portland, Oregonno site contact published
Providence Health & Services
Portland, Oregonno site contact published
UC San Diego Moores Cancer Center
La Jolla, Californiano site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Jospeh A Califano, MD · PRINCIPAL_INVESTIGATOR · University of California, San Diego
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Pathologic complete responseweek 7-10
Pathologic response is determined when surgery is performed at week 7-10 of study
- Major pathologic responseweek 7-10
Major pathologic response is defined as \<10% viable tumor cells in the resection specimen) after surgical resection